Source comparison
Thymosin Alpha-1 for Chronic Fatigue: Peptide Comparison
Thymosin Alpha-1 T-cell maturation, Treg upregulation, cytokine modulation 1.6mg SC twice weekly Reduces pro-inflammatory cytokines (IL-6, TNF-α), improves NK cell function, addresses immune dysregulation driving CFS Multiple RCTs in immune disorders; open-lab
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- T-cell maturation, Treg upregulation, cytokine modulation
- 1.6mg SC twice weekly
- Reduces pro-inflammatory cytokines (IL-6, TNF-α), improves NK cell function, addresses immune dysregulation driving CFS
- Multiple RCTs in immune disorders; open-label trials specific to CFS
- Best-evidenced immune modulator for fatigue with inflammatory/viral component
- Thymalin
- Thymic peptide extract, polypeptide mixture
- 10–30mg IM 2–3× weekly
- Thymic function restoration, broader immune support, less specific mechanism
- Primarily Eastern European observational studies
- Plausible mechanism but less characterized; consider as alternative if alpha-1 unavailable
- Cerebrolysin
- Neurotrophic peptide mixture derived from porcine brain
- 10–30mL IV daily for 10–20 sessions
- Neuroprotection, cognitive enhancement, may address central fatigue mechanisms
- RCTs in stroke and dementia; limited CFS-specific data
- Addresses cognitive symptoms and neuroinflammation but requires clinical IV administration
- Selank
- Synthetic analogue of tuftsin, anxiolytic peptide
- 300–600mcg intranasal daily
- Reduces anxiety-driven fatigue perception, modulates BDNF, no direct immune effects
- Small RCTs for anxiety; anecdotal fatigue reports
- Useful for comorbid anxiety worsening fatigue but doesn't address immune dysfunction
- Thymosin alpha-1 occupies the most specific mechanistic niche for chronic fatigue driven by immune dysregulation. It directly corrects the T-cell and cytokine abnormalities documented in CFS research, unlike peptides targeting only cognitive symptoms or general metabolic support. For researchers investigating fatigue syndromes with elevated inflammatory markers or suspected viral reactivation, thymosin alpha-1 represents the most evidence-backed peptide intervention currently available.